{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T04:25:44Z","timestamp":1740111944218,"version":"3.37.3"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ejca.2024.115058","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T17:23:38Z","timestamp":1727717018000},"page":"115058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Inadequate staging and excessive surveillance imaging: Evaluating the magnitude of benefit of targeted therapies in lung cancer"],"prefix":"10.1016","volume":"212","author":[{"given":"David J.","family":"Benjamin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.115058_bib1","unstructured":"Tagrisso Poised to Become Standard of Care in Unresectable Stage III EGFR-Mutated NSCLC. Precision Medicine Online. June 2, 2024. Accessed August 31, 2024. https:\/\/www.precisionmedicineonline.com\/precision-oncology\/tagrisso-poised-become-standard-care-unresectable-stage-iii-egfr-mutated-nsclc."},{"issue":"7","key":"10.1016\/j.ejca.2024.115058_bib2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115058_bib3","unstructured":"NCCN Guidelines Version 2.2018 Non-Small Cell Lung Cancer. Link: https:\/\/www2.tri-kobe.org\/nccn\/guideline\/archive\/lung2018\/english\/non_small.pdf. Accessed June 5, 2024."},{"key":"10.1016\/j.ejca.2024.115058_bib4","unstructured":"Protocol, pages 25\u201326. Link: https:\/\/www.nejm.org\/doi\/suppl\/10.1056\/NEJMoa2402614\/suppl_file\/nejmoa2402614_protocol.pdf. Accessed June 5, 2024."},{"issue":"15_suppl","key":"10.1016\/j.ejca.2024.115058_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.7502","article-title":"A randomized controlled trial (RCT) of 18F-flurodeoxyglucose (FDG) positron emission tomography (PET) versus conventional imaging (CI) in staging potentially resectable non-small cell lung cancer (NSCLC)","volume":"26","author":"Maziak","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115058_bib6","unstructured":"Protocol, page 204. Link: https:\/\/www.nejm.org\/doi\/suppl\/10.1056\/NEJMoa2402614\/suppl_file\/nejmoa2402614_protocol.pdf. Accessed June 5, 2024."},{"key":"10.1016\/j.ejca.2024.115058_bib7","unstructured":"Protocol, page 47. Link: https:\/\/www.nejm.org\/doi\/suppl\/10.1056\/NEJMoa2027071\/suppl_file\/nejmoa2027071_protocol.pdf. Accessed June 5, 2024."},{"key":"10.1016\/j.ejca.2024.115058_bib8","unstructured":"Protocol, page 295. Link: https:\/\/www.nejm.org\/doi\/suppl\/10.1056\/NEJMoa2310532\/suppl_file\/nejmoa2310532_protocol.pdf. Accessed June 5, 2024."},{"key":"10.1016\/j.ejca.2024.115058_bib9","unstructured":"Protocol, page 132. Link: https:\/\/www.nejm.org\/doi\/suppl\/10.1056\/NEJMoa2310532\/suppl_file\/nejmoa2310532_protocol.pdf. Accessed June 5, 2024."},{"key":"10.1016\/j.ejca.2024.115058_bib10","unstructured":"Protocol, page 257. Link: https:\/\/www.nejm.org\/doi\/suppl\/10.1056\/NEJMoa1704795\/suppl_file\/nejmoa1704795_protocol.pdf. Accessed June 5, 2024."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924010244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924010244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T21:31:00Z","timestamp":1737667860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924010244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":10,"alternative-id":["S0959804924010244"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115058","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inadequate staging and excessive surveillance imaging: Evaluating the magnitude of benefit of targeted therapies in lung cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115058"}}